I learned from Beijing Yimiao Shenzhou Biomedical Co., Ltd., that the company's first self-developed CAR-T cell drug, Poggiolensis injection, obtained a “Drug Registration Certificate” issued by the State Drug Administration to treat patients with recurrent or refractory large B-cell lymphoma in adults after second-line or above systematic treatment. This is also the first CAR-T cell drug approved in Beijing.

I learned from Beijing Yimiao Shenzhou Biomedical Co., Ltd., that the company's first self-developed CAR-T cell drug, Poggiolensis injection, obtained a “Drug Registration Certificate” issued by the State Drug Administration to treat patients with recurrent or refractory large B-cell lymphoma in adults after second-line or above systematic treatment. This is also the first CAR-T cell drug approved in Beijing.